Q-omics provides the consensus-scored ANKRD62 profile across patient tissues and cancer cell-line models. ANKRD62 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ANKRD62 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ANKRD62 RNA expression shows 18,177 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where ANKRD62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD62 survival associations across molecular data types. ANKRD62 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD62 RNA expression–survival associations across cancer types. High ANKRD62 expression shows unfavorable associations in ACC, UVM, KIRP, UCEC and READ, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ANKRD62 RNA expression.
This table summarizes ANKRD62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD62 shows lower tumor expression in COAD, THCA and READ and higher tumor expression in KIRC, UCEC and KIRP. The COAD box plot shows higher ANKRD62 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p < 0.001).
This table shows molecular features associated with ANKRD62 in patient tissues and cancer cell lines. In patient samples, ANKRD62 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD62 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
